Erythropoiesis-stimulating agent responsiveness and hemoglobin variability is associated with fat tissue index in hemodialysis patients with darbepoetin-alfa treatment: a prospective observational cohort study
- PMID: 39748660
- PMCID: PMC11985273
- DOI: 10.23876/j.krcp.24.070
Erythropoiesis-stimulating agent responsiveness and hemoglobin variability is associated with fat tissue index in hemodialysis patients with darbepoetin-alfa treatment: a prospective observational cohort study
Abstract
Background: Although the introduction of erythropoietin-stimulating agents (ESAs) has led to better clinical outcomes in patients undergoing hemodialysis (HD), fluctuations in hemoglobin (Hb) levels, known as Hb variability, are frequently observed. However, only a few studies have evaluated the association between Hb variability and nutritional status in patients undergoing HD.
Methods: In this prospective study conducted between March 1, 2020, and June 1, 2022, we included 109 patients aged over 20 years undergoing HD and receiving darbepoetin. We checked the average NESP (darbepoetin-alfa; Kyowa Kirin Korea Co., Ltd.) dose weekly and nutritional parameters such as body mass index (BMI), fat tissue index (FTI), and lean tissue index obtained by body composition monitoring. Additionally, the ESA resistance index (ERI) and the coefficient of variation of Hb (Hb-CV) were evaluated.
Results: In this study, the mean age of the patients was 64.0 ± 11.9 years, and 55.0% were male. Mean Hb was 10.7 ± 1.3 g/dL. Patients were categorized into three groups according to the ERI or Hb-CV tertiles. The highest ERI tertile was associated with lower Hb levels, BMI, and FTI. The highest Hb-CV tertile was associated with lower BMI and FTI. In multiple linear regression analysis, FTI was negatively associated with ERI (β = -0.218, p = 0.01) and Hb-CV (β = -0.181, p = 0.04).
Conclusion: These findings suggest that FTI is negatively associated with ERI and Hb-CV, and that ESAs responsiveness and Hb variability are associated with FTI in patients undergoing HD with darbepoetin treatment.
Keywords: Body composition; Darbepoetin; Fat tissue index; Hemoglobin variability; Nutritional status.
Conflict of interest statement
All authors have no conflicts of interest to declare.
Figures


Similar articles
-
Phase angle values, a good indicator of nutritional status, are associated with median value of hemoglobin rather than hemoglobin variability in hemodialysis patients.Ren Fail. 2021 Dec;43(1):327-334. doi: 10.1080/0886022X.2020.1870137. Ren Fail. 2021. PMID: 33567950 Free PMC article.
-
Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.J Manag Care Pharm. 2008 Nov-Dec;14(9):858-69. doi: 10.18553/jmcp.2008.14.9.858. J Manag Care Pharm. 2008. PMID: 19006442 Free PMC article.
-
Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.PLoS One. 2015 Nov 20;10(11):e0143348. doi: 10.1371/journal.pone.0143348. eCollection 2015. PLoS One. 2015. PMID: 26588085 Free PMC article.
-
Darbepoetin alfa.Drugs. 2001;61(14):2097-104; discussion 2105-6. doi: 10.2165/00003495-200161140-00007. Drugs. 2001. PMID: 11735636 Review.
-
Darbepoetin alfa: a novel erythropoiesis-stimulating protein.Drugs Today (Barc). 2003 Jul;39(7):477-95. doi: 10.1358/dot.2003.39.7.799441. Drugs Today (Barc). 2003. PMID: 12973399 Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources